537 related articles for article (PubMed ID: 16763589)
1. Private biotech 2004--the numbers.
Hodgson J
Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
[TBL] [Abstract][Full Text] [Related]
2. State of biotech sector--2005.
Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):603. PubMed ID: 16763577
[No Abstract] [Full Text] [Related]
3. Public biotechnology 2005--the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
[TBL] [Abstract][Full Text] [Related]
4. Public biotechnology 2003-the numbers.
Lähteenmäki R; Baker M
Nat Biotechnol; 2004 Jun; 22(6):665-70. PubMed ID: 15175683
[No Abstract] [Full Text] [Related]
5. Public biotech 2006 - the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294
[No Abstract] [Full Text] [Related]
6. Public biotechnology 2002--the numbers.
Lähteenmäki R; DeFrancesco L
Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
[No Abstract] [Full Text] [Related]
7. Public biotech 2007--the numbers.
Lawrence S; Lähteenmäki R
Nat Biotechnol; 2008 Jul; 26(7):753-62. PubMed ID: 18612294
[TBL] [Abstract][Full Text] [Related]
8. Growth and profitability in small privately held biotech firms: preliminary findings.
Brännback M; Carsrud A; Renko M; Ostermark R; Aaltonen J; Kiviluoto N
N Biotechnol; 2009 Jun; 25(5):369-76. PubMed ID: 19491050
[TBL] [Abstract][Full Text] [Related]
9. 2007--a banner year for biotech.
Lawrence S
Nat Biotechnol; 2008 Feb; 26(2):150. PubMed ID: 18259162
[No Abstract] [Full Text] [Related]
10. Lack of private financing hobbles emerging biotech regions.
Jia H; Jayarama KS; Astvatsaturyan M
Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
[No Abstract] [Full Text] [Related]
11. Editorial: Biotech in the financial crisis.
Jungbauer A
Biotechnol J; 2009 Aug; 4(8):1095. PubMed ID: 19685457
[No Abstract] [Full Text] [Related]
12. Biotech sector ponders potential 'bloodbath'.
Mitchell P
Nat Biotechnol; 2009 Jan; 27(1):3-4. PubMed ID: 19131974
[No Abstract] [Full Text] [Related]
13. Public biotechnology 2001--the numbers.
Lähteenmäki R; Fletcher L
Nat Biotechnol; 2002 Jun; 20(6):551-5. PubMed ID: 12042853
[No Abstract] [Full Text] [Related]
14. Public biotech 2010--the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2011 Jul; 29(7):585-91. PubMed ID: 21747381
[No Abstract] [Full Text] [Related]
15. Insights into US public biotech sector using patenting trends.
Aggarwal S; Gupta V; Bagchi-Sen S
Nat Biotechnol; 2006 Jun; 24(6):643-51. PubMed ID: 16763590
[TBL] [Abstract][Full Text] [Related]
16. Perspective: Biotech funding trends: Insights from entrepreneurs and investors.
Gruber AC
Biotechnol J; 2009 Aug; 4(8):1102-5. PubMed ID: 19685460
[TBL] [Abstract][Full Text] [Related]
17. Biotech patenting slows in 2004.
Lawrence S
Nat Biotechnol; 2005 Oct; 23(10):1198. PubMed ID: 16211048
[No Abstract] [Full Text] [Related]
18. Wrong numbers?
Nat Biotechnol; 2010 Aug; 28(8):761. PubMed ID: 20697382
[No Abstract] [Full Text] [Related]
19. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
20. Executive compensation at private biotech companies: a competitive environment.
Rychlik B; Dipierro M
Nat Biotechnol; 2008 Jan; 26(1):133-4. PubMed ID: 18183026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
